AtonRa Partners Has $341,000 Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

AtonRa Partners decreased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.8% during the 4th quarter, HoldingsChannel reports. The fund owned 5,496 shares of the medical equipment provider’s stock after selling 403 shares during the period. AtonRa Partners’ holdings in Lantheus were worth $341,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Tucker Asset Management LLC grew its stake in shares of Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 282 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 225 shares during the last quarter. Covestor Ltd grew its stake in shares of Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 203 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Lantheus by 36.6% in the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 156 shares during the last quarter. Finally, NBC Securities Inc. acquired a new stake in shares of Lantheus in the third quarter worth $46,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH traded up $1.70 during midday trading on Monday, reaching $67.26. 1,101,107 shares of the company traded hands, compared to its average volume of 1,031,756. The firm has a market cap of $4.61 billion, a PE ratio of 14.50 and a beta of 0.54. The stock’s 50-day simple moving average is $61.62 and its 200-day simple moving average is $62.64. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $100.85. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. The company had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a research report on Friday, February 23rd. Truist Financial reaffirmed a “buy” rating and issued a $82.00 target price (up from $80.00) on shares of Lantheus in a research report on Monday, February 26th. Finally, B. Riley raised their target price on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $104.71.

Insider Buying and Selling at Lantheus

In related news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. Over the last three months, insiders sold 94,545 shares of company stock valued at $6,169,936. 2.10% of the stock is currently owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.